Why I Invest in Critical Infrastructure

The venture world has a pattern problem. Capital floods toward consumer apps, AI wrappers, and social platforms — sectors with fast feedback loops, viral coefficients, and legible growth metrics. I understand the logic. These are easier businesses to underwrite.

But the most important companies being built right now are not consumer apps. They are the companies rebuilding the invisible scaffolding of civilization: the compliance rails that let regulated industries function, the orbital infrastructure that modern economies increasingly depend on, and the biotechnology that may finally address how long and how well humans live.

This is why I founded Froskr Capital.

The Core Thesis: Non-Negotiable Problems

My investment framework begins with a single question: Is this a problem the world can afford to ignore?

Most startup problems are optional. Faster food delivery is nice to have. A better project management tool improves productivity at the margin. These are real businesses, but their problems are negotiable — the world can muddle along without solutions.

Critical infrastructure problems are different. Compliance failures cost financial institutions hundreds of billions in fines annually and destroy careers. A compromised power grid or water treatment system is a national security event. The longevity gap — the years humans spend in poor health before dying — costs the global economy trillions per year in lost productivity and healthcare spend. These are non-negotiable problems.

Non-negotiable problems have a venture property that is underappreciated: they create captive demand. When your customer must solve a problem, sales cycles compress, churn rates collapse, and switching costs compound over time. The best critical infrastructure businesses don't grow through virality — they grow through necessity, and they stick.

Compliance and Cybersecurity

Regulatory complexity is accelerating, not slowing down. DORA, SEC cybersecurity disclosure rules, AI governance frameworks, ESG reporting mandates — every new regulation is a new surface area for compliance failure, and a new market for the founders who solve it.

I back founders in this space who understand that compliance is not a checkbox exercise — it is an operational capability that enterprises are increasingly willing to pay for as a managed service. The best companies here are not building audit tools; they are embedding themselves into the workflows that would have to exist anyway, and making those workflows defensible.

What I look for: deep regulatory domain knowledge in the founding team, a wedge in a specific vertical before expanding horizontally, and a product that makes the compliance officer's life structurally better rather than just more documented.

Space Exploration

Space has crossed from science project to infrastructure. GPS, weather forecasting, financial transaction timing, precision agriculture, broadband in remote regions — the global economy runs on orbital assets. And that dependency is growing as launch costs fall and new orbital regimes open up.

I am not investing in moon bases. I am investing in the picks-and-shovels layer that makes the new space economy function: ground station software, satellite operations platforms, space traffic management, and the materials and propulsion technologies that make the next generation of missions possible.

The sovereign dimension matters here too. Every major economy is treating space infrastructure as a strategic priority. That means long-term procurement relationships, multi-year contracts, and a customer base — governments and defense primes — that does not disappear when interest rates change.

What I look for: founders with aerospace or defense domain credibility, a clear path to a first government or commercial anchor contract, and technology with dual-use applicability that expands the total addressable market.

Longevity Biotech

The longevity thesis is simple: aging is the largest upstream risk factor for nearly every disease that kills people at scale. Cancer, cardiovascular disease, neurodegeneration — these are not independent problems. They are downstream consequences of the biology of aging. Companies that attack the upstream cause are working on the highest-leverage intervention in medicine.

I am interested in the companies that are translating the last decade of longevity science — senolytics, epigenetic reprogramming, metabolic interventions, NAD+ pathway modulation — into clinical-stage and near-clinical products. The science has never been further along. The regulatory path is becoming clearer. And the demographic tailwind is the most predictable force in global economics.

What I look for: scientific founders with publications in the core longevity biology, a specific indication with a clear regulatory path, and a platform rather than a single-compound approach.

Why a Syndicate

Froskr operates as an AngelList syndicate rather than a traditional fund for a specific reason: the LP base should be an asset, not just a source of capital.

In critical infrastructure sectors, the most valuable thing an investor can offer — beyond the check — is a warm introduction to a regulated customer, a government contact, a domain expert who can diligence a technical claim, or a former operator who has navigated the compliance landscape the founder is entering. A syndicate model lets me build that network deliberately, with LPs who have genuine domain expertise in the sectors I invest in.

If you are building in Compliance and Cybersecurity, Space Exploration, or Longevity Biotech, I want to hear from you. And if you have domain expertise in any of these sectors and want to co-invest alongside me, the syndicate is open.

Vishak Menon is the Principal Syndicate Lead at Froskr Capital. You can reach him at vishak@froskr.com or apply to the syndicate at angellist.com/s/froskr.